Transcript of the Earning Call held on Friday, 22 May 2026 with respect to the Audited (Standalone and Consolidated) Financial results of the Company for the quarter and year ended March 31, 2026.
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suraksha Diagnostic reported FY26 revenue of INR3,104.1 million (23.1% YoY growth) with blended EBITDA margin of 31.73%. The company served 1.37 million patients with 8.16 million tests, growing revenue per patient to INR2,264. Mature centers continue to deliver strong 36-37% EBITDA margins while new centers are still ramping up with negative 5.5% margins. The company expanded to 68 centers (added 2 hubs, 11 spokes, and 3 PPP centers during FY26). For FY27, management guided revenue growth of ~15% and EBITDA margin to stabilize at ~33% as new centers scale, with medium-term target of 35% and long-term potential of 38-39%. Planned FY27 capex is around INR70 crore to add 5 hubs and 8 spokes across West Bengal, Bihar, Tripura, and Jharkhand.
The earnings call shows solid operational performance with strong revenue growth driven by premium test mix and specialized diagnostics. However, EBITDA margins compressed from 33.8% to 31.8% due to new center ramp-up costs. Management's explicit guidance on margin recovery trajectory (33% in FY27 → 35% medium-term → 38-39% long-term) provides visibility for shareholders on profitability improvement as newer centers mature.